Bart Cornelissen
Impact in
-
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Oncology top 5%
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
Papers in
-
- Radiopharmaceutical Chemistry and Applications 46
- Medical Imaging Techniques and Applications 21
- Monoclonal and Polyclonal Antibodies Research 17
- Oncology 45
- HER2/EGFR in Cancer Research 11
- PARP inhibition in cancer therapy 10
- Cancer-related Molecular Pathways 8
- Co-authors
- Veerle KersemansKatherine A. VallisJames C. KnightRaymond M. ReillySean SmartKristin McLartyMichael MosleyVéronique Gouverneur
- Journals
- Journal of Nuclear Medicine (19 papers)Nuclear Medicine and Biology (15 papers)European Journal of Nuclear Medicine and Molecular Imaging (11 papers)EJNMMI Research (5 papers)Cancer Biotherapy and Radiopharmaceuticals (3 papers)
- Partner nations
- United KingdomBelgiumNetherlands
In The Last Decade
Bart Cornelissen
109 papers receiving 2.5k citations
Peers
Comparison fields: 5 of 119
- Radiology, Nuclear Medicine and Imaging 1.1k
- Oncology 948
- Pharmaceutical Science 118
- Cancer Research 268
- Structural Biology 25
Countries citing papers authored by Bart Cornelissen
This map shows the geographic impact of Bart Cornelissen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Cornelissen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Cornelissen more than expected).
Fields of papers citing papers by Bart Cornelissen
This network shows the impact of papers produced by Bart Cornelissen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Cornelissen. The network helps show where Bart Cornelissen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bart Cornelissen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 8 | |
| 4 | 2022 | 0 | |
| 5 | 2019 | 17 | |
| 6 | 2019 | 18 | |
| 7 | 2019 | 1 | |
| 8 | 2018 | 16 | |
| 9 | 2017 | 29 | |
| 10 | 2017 | 21 | |
| 11 | 2017 | 16 | |
| 12 | 2013 | 19 | |
| 13 | Targeting {gamma}H2AX during oncogenesis with Auger electron therapy delays tumor onset | 2013 | 1 |
| 14 | 2011 | 57 | |
| 15 | 2009 | 58 | |
| 16 | 2009 | 11 | |
| 17 | 2008 | 32 | |
| 18 | 2008 | 103 | |
| 19 | Indium-111 labeled anti-CD33 monoclonal antibodies (mAbs) modified with nuclear-localizing sequences (NLS) kill mitoxantrone-resistant HL-60 acute myelogenous leukemia (AML) cells | 2006 | 1 |
| 20 | In vivo evaluation of [I-123]-2-Iodo-D-Phenylalanine in tumour inoculated athymic mice by means of SPECT as a potential diagnostic and radionuclide therapy tool. | 2004 | 1 |
About Bart Cornelissen
Bart Cornelissen is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Pharmaceutical Science, Cancer Research and Structural Biology, having authored 112 papers that have together received 2.5k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (46 papers), Medical Imaging Techniques and Applications (21 papers), DNA Repair Mechanisms (17 papers), Monoclonal and Polyclonal Antibodies Research (17 papers), HER2/EGFR in Cancer Research (11 papers), PARP inhibition in cancer therapy (10 papers), Cancer-related Molecular Pathways (8 papers) and Radiation Therapy and Dosimetry (8 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.1k citations), Oncology (948 citations), Pharmaceutical Science (118 citations), Cancer Research (268 citations) and Structural Biology (25 citations). Bart Cornelissen has collaborated with scholars based in United Kingdom, Belgium and Netherlands. Frequent co-authors include Veerle Kersemans, Katherine A. Vallis, James C. Knight, Raymond M. Reilly, Sean Smart, Kristin McLarty, Michael Mosley, Véronique Gouverneur, Philip D. Allen and Ruth J. Muschel. Their work appears in journals such as Journal of Nuclear Medicine, Nuclear Medicine and Biology, European Journal of Nuclear Medicine and Molecular Imaging, EJNMMI Research and Cancer Biotherapy and Radiopharmaceuticals.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.